As reported in Figure 2B, AX09 induced high levels of anti-xCT IgG1 and IgG2a that, through FcγR-binding, could promote efficient anti-cancer mechanisms [43], which, in the case of IgG2a, include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This evidence concerns the gene FCGR2A and cancer.